Incannex Healthcare (IXHL) Competitors $0.58 -0.04 (-7.05%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$0.57 -0.01 (-1.72%) As of 09/4/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IXHL vs. IRD, ZIVO, RPTX, INKT, CVM, COEP, KALA, MNOV, GNTA, and INMBShould you be buying Incannex Healthcare stock or one of its competitors? The main competitors of Incannex Healthcare include Opus Genetics (IRD), ZIVO Bioscience (ZIVO), Repare Therapeutics (RPTX), MiNK Therapeutics (INKT), CEL-SCI (CVM), Coeptis Therapeutics (COEP), KALA BIO (KALA), MediciNova (MNOV), Genenta Science (GNTA), and INmune Bio (INMB). These companies are all part of the "pharmaceutical products" industry. Incannex Healthcare vs. Its Competitors Opus Genetics ZIVO Bioscience Repare Therapeutics MiNK Therapeutics CEL-SCI Coeptis Therapeutics KALA BIO MediciNova Genenta Science INmune Bio Incannex Healthcare (NASDAQ:IXHL) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk. Is IXHL or IRD more profitable? Incannex Healthcare has a net margin of 0.00% compared to Opus Genetics' net margin of -377.89%. Incannex Healthcare's return on equity of -342.92% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Incannex HealthcareN/A -342.92% -148.64% Opus Genetics -377.89%-384.33%-148.90% Does the media prefer IXHL or IRD? In the previous week, Opus Genetics had 4 more articles in the media than Incannex Healthcare. MarketBeat recorded 6 mentions for Opus Genetics and 2 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.50 beat Opus Genetics' score of 0.49 indicating that Incannex Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incannex Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate IXHL or IRD? Opus Genetics has a consensus target price of $7.33, suggesting a potential upside of 472.92%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Incannex Healthcare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, IXHL or IRD? Incannex Healthcare has a beta of 7.66, meaning that its share price is 666% more volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500. Do insiders and institutionals have more ownership in IXHL or IRD? 0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 15.5% of Incannex Healthcare shares are owned by insiders. Comparatively, 6.6% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, IXHL or IRD? Incannex Healthcare has higher earnings, but lower revenue than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIncannex Healthcare$10K1,706.94-$18.46M-$1.21-0.48Opus Genetics$10.99M6.98-$57.53M-$1.92-0.67 SummaryIncannex Healthcare beats Opus Genetics on 10 of the 16 factors compared between the two stocks. Get Incannex Healthcare News Delivered to You Automatically Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IXHL vs. The Competition Export to ExcelMetricIncannex HealthcareMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.37M$2.55B$5.76B$9.85BDividend YieldN/A49.35%6.67%4.51%P/E Ratio-0.4822.9075.9926.43Price / Sales1,706.94714.55546.94119.09Price / CashN/A169.7737.0558.92Price / Book3.225.3910.916.06Net Income-$18.46M$32.95M$3.29B$266.28M7 Day Performance-11.99%1.08%0.18%-0.32%1 Month Performance42.65%6.32%6.26%3.44%1 Year Performance-65.88%-0.28%51.54%23.11% Incannex Healthcare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IXHLIncannex Healthcare0.5506 of 5 stars$0.58-7.1%N/A-65.7%$18.37M$10K-0.483Short Interest ↓Gap DownIRDOpus Genetics1.9249 of 5 stars$1.15+0.4%$7.33+537.7%N/A$68.90M$10.99M-0.6014News CoverageZIVOZIVO Bioscience0.0688 of 5 stars$18.00+4.7%N/A+49.8%$68.71M$15.85K-3.6910Gap DownHigh Trading VolumeRPTXRepare Therapeutics3.4907 of 5 stars$1.59+2.6%$4.50+183.0%-39.0%$68.31M$53.48M-0.62180News CoverageINKTMiNK Therapeutics1.7735 of 5 stars$14.90-0.3%$37.50+151.7%+72.0%$67.35MN/A-5.1730Short Interest ↑CVMCEL-SCI0.4022 of 5 stars$9.52+3.8%N/A-65.1%$65.52MN/A-19.8343Short Interest ↑Gap UpCOEPCoeptis Therapeutics1.4614 of 5 stars$13.46+0.2%N/A+203.2%$64.88MN/A-2.322Positive NewsShort Interest ↓KALAKALA BIO2.8373 of 5 stars$9.21+8.4%$13.00+41.2%+141.4%$64.65M$3.89M-1.3630News CoverageAnalyst UpgradeMNOVMediciNova1.9347 of 5 stars$1.31+1.7%$7.00+433.4%-24.0%$64.37M$1M-5.2510Gap UpGNTAGenenta Science2.7635 of 5 stars$3.51-4.4%$25.00+612.3%-13.6%$64.20MN/A0.007Gap DownINMBINmune Bio2.2036 of 5 stars$2.41+2.6%$18.40+663.5%-68.8%$64.06M$10K-0.9710 Related Companies and Tools Related Companies Opus Genetics Alternatives ZIVO Bioscience Alternatives Repare Therapeutics Alternatives MiNK Therapeutics Alternatives CEL-SCI Alternatives Coeptis Therapeutics Alternatives KALA BIO Alternatives MediciNova Alternatives Genenta Science Alternatives INmune Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IXHL) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incannex Healthcare Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incannex Healthcare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
